NVO Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$46.74median target· current $41.72 (+12.0%)14 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
45 articles · sorted by datePage 1 of 3 · 45 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio10.45Forward 12.99
EPS (TTM)$3.99-20.6% YoY
Profit margin35.3%HEALTHCARE
Market cap$184.27BLarge cap
Valuation
- Forward P/E
- 12.99
- PEG ratio
- 3.01
- P/B
- 5.48
- P/S (TTM)
- 0.56
- EV/EBITDA
- 8.89
Profitability & growth
- ROE (TTM)
- 59.8%
- Operating margin
- 42.5%
- Revenue growth YoY
- 2.1%
- Dividend yield
- 4.3%
- Beta
- 0.34
Last earnings
Aug 5, 2026 · Estimate $0.82 · Reported $0.96
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Novo Nordisk A/S
Company profileNovo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- NOVO ALLE 1, BAGSVAERD, DENMARK
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$184.27B
Shares outstanding$3.34B
52W high$61.11
52W low$34.15
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent